Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification

Cancer Science

Volumn 105, Issue 10, 2014, Pages 1245-1253

  Jang, Won Jun ^a   Jung, Sung Keun ^b   Kang, Jong Soon ^c   Jeong, Joo Won ^d   Bae, Moon Kyoung ^e   Joo, Sang Hoon ^f   Park, Gyu Hwan ^g   Kundu, Joydeb K ^a   Hong, Young Soo ^c   Jeong, Chul Ho ^a  

^a Keimyung University   (South Korea)

^b Korea Food Research Institute   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

^e Pusan National University   (South Korea)

^f Catholic University of Daegu   (South Korea)

^g Kyungpook National University   (South Korea)

Author keywords

Gefitinib; Hsp90; Non benzoquinone GA; Non small cell lung cancer; WK88 1

Indexed keywords

18-DEHYDROXYL-17-DEMETHOXYREBLASTATIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB3 PROTEIN, HUMAN; GEFITINIB; GELDANAMYCIN; MACROCYCLIC LACTAM; MET PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE AMPLIFICATION; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, ERBB-3;

EID: 84911192025     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12497     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-46.
3. Lynch TJ, Adjei AA, Bunn PA Jr et al. Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res 2006; 12: 4365s-71s.
4. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238-47.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
6. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121-8.
7. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57.
8. Jackman D, Pao W, Riely GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2011; 28: 357-60.
9. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
10. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
11. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
12. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
13. Engelman JA, Zejnullahu K, Gale CM et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-32.
14. Zhou W, Ercan D, Chen L et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009; 462: 1070-4.
15. Tang Z, Du R, Jiang S et al. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer 2008; 99: 911-22.
16. Li D, Shimamura T, Ji H et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
17. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010; 70: 1625-34.
18. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
19. da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005; 65: 10686-91.
20. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005; 65: 6401-8.
21. Webb CP, Hose CD, Koochekpour S et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 2000; 60: 342-9.
22. Yang S, Qu S, Perez-Tores M et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 2006; 66: 6990-7.
23. Chiosis G. Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin Ther Targets 2006; 10: 37-50.
24. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004; 10: 283-90.
25. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005; 10: 137-49.
26. Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003; 3: 213-7.
27. Gooljarsingh LT, Fernandes C, Yan K et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A 2006; 103: 7625-30.
28. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
29. Pratilas CA, Hanrahan AJ, Halilovic E et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-83.
30. Shimamura T, Li D, Ji H et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008; 68: 5827-38.
31. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3: 377-83.
32. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305-15.
33. Brough PA, Aherne W, Barril X et al. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008; 51: 196-218.
34. Chiosis G, Lucas B, Shtil A, Huezo H, Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002; 10: 3555-64.
35. Banerji U, Sain N, Sharp SY et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 2008; 62: 769-78.
36. Cysyk RL, Parker RJ, Barchi JJ Jr, Steeg PS, Hartman NR, Strong JM. Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. Chem Res Toxicol 2006; 19: 376-81.
37. Kim W, Lee D, Hong SS et al. Rational biosynthetic engineering for optimization of geldanamycin analogues. ChemBioChem 2009; 10: 1243-51.
38. Kim W, Lee JS, Lee D et al. Mutasynthesis of geldanamycin by the disruption of a gene producing starter unit: generation of structural diversity at the benzoquinone ring. ChemBioChem 2007; 8: 1491-4.
39. Amann J, Kalyankrishna S, Massion PP et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005; 65: 226-35.
40. Guo A, Villen J, Kornhauser J et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008; 105: 692-7.
41. Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 2011; 105: 807-13.
42. Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF Receptor Activates MET through MAPK to Enhance Non-Small Cell Lung Carcinoma Invasion and Brain Metastasis. Cancer Res 2013; 73: 5053-65.
43. Xu L, Nilsson MB, Saintigny P et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010; 29: 2616-27.
44. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
45. Camphausen K, Tofilon PJ. Inhibition of Hsp90: a multitarget approach to radiosensitization. Clin Cancer Res 2007; 13: 4326-30.
46. Gerbin CS, Landgraf R. Geldanamycin selectively targets the nascent form of ERBB3 for degradation. Cell Stress Chaperones 2010; 15: 529-44.